Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy

Journal of Clinical Microbiology

Volumn 48, Issue 5, 2010, Pages 1911-1912

  Pascual Pareja, José F ^a,b   Martínez Prats, Lorena ^a   Luczkowiak, Joanna ^a   Fiorante, Silvana ^a   Rubio, Rafael ^a   Pulido, Federico ^a   Otero, Joaquín R ^a   Delgado, Rafael ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPUTER PROGRAM; DIAGNOSTIC KIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951864344     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02388-09     Document Type: Article

References (9)

1. Arribas, J. R., R. Delgado, A. Arranz, R. Muñoz, J. Portilla, J. Pasquau, M. J. Pérez-Elias, J. A. Iribarren, R. Rubio, A. Ocampo, M. Sánchez-Conde, H. Knobel, P. Arazo, J. Sanz, J. López-Aldeguer, M. L. Montes, F. Pulido, et al. 2009. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J. Acquir. Immune Defic. Syndr. 51:147-152.
2. Dinoso, J. B., S. Y. Kim, A. M. Wiegand, S. E. Palmer, S. J. Gange, L. Cranmer, A. O'Shea, M. Callender, A. Spivak, T. Brennan, M. F. Kearney, M. A. Proschan, J. M. Mican, C. A. Rehm, J. M. Coffin, J. W. Mellors, R. F. Siliciano, and F. Maldarelli. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 106:9403-9408.
3. Hammer, S. M., Jr., J. J. Eron, P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. Montaner, D. D. Richman, P. G. Yeni, and P. A. Volberding. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
4. Kieffer, T. L., M. M. Finucane, R. E. Nettles, T. C. Quinn, K. W. Broman, S. C. Ray, D. Persaud, and R. F. Siliciano. 2004. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189:1452-1465.
5. Maldarelli, F., S. Palmer, M. S. King, A. Wiegand, M. A. Polis, J. Mican, J. A. Kovacs, R. T. Davey, D. Rock-Kress, R. Dewar, S. Liu, J. A. Metcalf, C. Rehm, S. C. Brun, G. J. Hanna, D. J. Kempf, J. M. Coffin, and J. W. Mellors. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3:e46. (Pubitemid 46683483)
6. Palmer, S., F. Maldarelli, A. Wiegand, B. Bernstein, G. J. Hanna, S. C. Brun, D. J. Kempf, J. W. Mellors, J. M. Coffin, and M. S. King. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
7. Palmer, S., A. P. Wiegand, F. Maldarelli, H. Bazmi, J. M. Mican, M. Polis, R. L. Dewar, A. Planta, S. Liu, J. A. Metcalf, J. W. Mellors, and J. M. Coffin. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41:4531-4536.
8. Siliciano, J. D., J. Kajdas, D. Finzi, T. C. Quinn, K. Chadwick, J. B. Margolick, C. Kovacs, S. J. Gange, and R. F. Siliciano. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 T cells. Nat. Med. 6:727-728.
9. Wilkin, T. J., J. E. McKinnon, A. G. DiRienzo, K. Mollan, C. V. Fletcher, D. M. Margolis, B. Bastow, G. Thal, W. Woodward, C. Godfrey, A. Wiegand, F. Maldarelli, S. Palmer, J. M. Coffin, J. W. Mellors, and S. Swindells. 2009. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J. Infect. Dis. 199:866-871.